Cost-effectiveness of rituximab as maintenance therapy in patients with follicular non-Hodgkin lymphoma after responding to first-line rituximab plus chemotherapy

Leukemia and Lymphoma

Volumn 53, Issue 12, 2012, Pages 2371-2377

  Hornberger, John ^a,b   Chien, Rebecca ^a   Friedmann, Mark ^c   Han, Leona ^d   Shewade, Ashwini ^a   Satram Hoang, Sacha ^e   Reyes, Carolina ^f,g  

^a Cedar Associates LLC   (United States)

^b STANFORD UNIVERSITY   (United States)

^c Columbia University Mailman School of Public Health ^*  (United States)

^d MAYO CLINIC   (United States)

^e QD Research Inc   (United States)

^f GENENTECH INC   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cost effectiveness; Follicular non Hodgkin lymphoma; Rituximab

Indexed keywords

BENDAMUSTINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; LENALIDOMIDE; MITOXANTRONE; PREDNISOLONE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ARTICLE; BODY SURFACE; CANCER GROWTH; CANCER MORTALITY; COST EFFECTIVENESS ANALYSIS; DRUG COST; FOLLICULAR LYMPHOMA; HUMAN; INDUCTION CHEMOTHERAPY; MAINTENANCE THERAPY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY ADJUSTED LIFE YEAR; TREATMENT DURATION;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE III AS TOPIC; COST-BENEFIT ANALYSIS; DISEASE-FREE SURVIVAL; DRUG COSTS; FEMALE; HUMANS; LYMPHOMA, FOLLICULAR; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84868343934     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.694429     Document Type: Article

References (36)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Anderson JR, Armitage JO, Weisenburger DD. Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project. Ann Oncol 1998;9:717-720. (Pubitemid 28394156)
3. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998;16:2780-2795. (Pubitemid 28363044)
4. Gallagher CJ, Gregory WM, Jones AE, et al. Follicular lymphoma: prognostic factors for response and survival. J Clin Oncol 1986;4: 1470-1480. (Pubitemid 17183570)
5. Horning SJ. Natural history of and therapy for the indolent non-Hodgkin' s lymphomas. Semin Oncol 1993;20:75-88. (Pubitemid 23319044)
6. Rohatiner AZ, Lister TA. The clinical course of follicular lymphoma. Best Pract Res Clin Haematol 2005;18:1-10. (Pubitemid 40197862)
7. Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood 2004;104:1258-1265. (Pubitemid 39166497)
8. Swenson WT, Wooldridge JE, Lynch CF, et al. Improved survival of follicular lymphoma patients in the United States. J Clin Oncol 2005;23:5019-5026. (Pubitemid 46224008)
9. Friedberg JW, Taylor MD, Cerhan JR, et al. Follicular lymphoma in the United States: first report of the national LymphoCare study. J Clin Oncol 2009;27:1202-1208.
10. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology v.1.2010, Non Hodgkin's Lymphomas. 2010. Available from: http://www.nccn.org/professionals/physician-gls/f-guidelines.asp
11. Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2010;377:42-51.
12. Friedberg JW. Rituximab maintenance in follicular lymphoma: PRIMA. Lancet 2011;377:4-6.
13. Gold M, Siegel J, Russell L, et al. Cost-effectiveness in health and medicine. 1st ed. New York: Oxford University Press; 1996.
14. Russell LB, Gold MR, Siegel JE, et al. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-effectiveness in Health and Medicine. JAMA 1996;276:1172-1177. (Pubitemid 26329746)
15. Siegel JE, Weinstein MC, Russell LB, et al. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-effectiveness in Health and Medicine. JAMA 1996;276:1339-1341. (Pubitemid 26346934)
16. Weinstein MC, Siegel JE, Russell LB, et al. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 1996;276:1253-1258. (Pubitemid 26337709)
17. v an Oers MH, Van Glabbeke M, Giurgea L, et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol 2010;28:2853-2858.
18. Arias E. National Vital Statistics Report. 2010. Available from: http://www.cdc.gov/nchs/data/nvsr/nvsr58/nvsr58-21.pdf
19. Centers for Medicare and Medicaid Services. CMS Physician Fee Schedule. 2010. Available from: http://www.cms.gov/apps/physicianfee-schedule/search/ search-criteria.aspx
20. List of MS-DRGs, relative weighting factors and geometric and arithmetic mean length of stay. 2010. Available from: http://www.cms. gov/ AcuteInpatientPPS/10FR/itemdetail.asp
21. Guadagnolo BA, Punglia RS, Kuntz KM, et al. Cost-effectiveness analysis of computerized tomography in the routine follow-up of patients after primary treatment for Hodgkin's disease. J Clin Oncol 2006;24:4116-4122. (Pubitemid 46622287)
22. Hayslip J, Simpson K. Cost-effectiveness of extended adjuvant rituximab for US patients aged 65-70 years with follicular lymphoma in second remission. Clin Lymphoma Myeloma 2008;8:166-170.
23. Wild D, Walker M, Pettengell R, et al. Utility elicitation in patients with follicular lymphoma. Value Health 2006;9:A294.
24. Pettengell R, Donatti C, Hoskin P, et al. The impact of follicular lymphoma on health-related quality of life. Ann Oncol 2008;19: 570-576. (Pubitemid 351325681)
25. Weinstein M, O' B rien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices-Modeling Studies. Value Health 2003;6:9-17. (Pubitemid 36228345)
26. Lipscomb J, Weinstein M, Torrance GW. Time preference. In: Gold M, Siegel J, Russell L, et al., editors. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996. pp 214-246.
27. Briggs A, Claxton K, Sculpher M. Decision modelling for health economic evaluation. Oxford: Oxford University Press; 2006.
28. Kutikova L, Bowman L, Chang S, et al. Medical costs associated with non-Hodgkin's lymphoma in the United States during the first two years of treatment. Leuk Lymphoma 2006;47:1535-1544. (Pubitemid 44364018)
29. v an Oers MH, Van Glabbeke M, Giurgea L, et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol 2010;28:2853-2858.
30. Hainsworth JD, Litchy S, Burris HA 3rd, et al. Rituximab as firstline and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol 2002;20:4261-4267. (Pubitemid 35191030)
31. Hochster H, Weller E, Gascoyne RD, et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progressionfree survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. J Clin Oncol 2009;27:1607-1614.
32. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005;105:1417-1423. (Pubitemid 40223656)
33. Martinelli G, Schmitz SF, Utiger U, et al. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. J Clin Oncol 2010;28:4480-4484.
34. Vidal L, Gafter-Gvili A, Salles G, et al. Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials. J Natl Cancer Inst 2011;103:1799-1806.
35. International Society of Pharmacoeconomic Outcomes and Research, Society of Medical Decision Making. Joint Modeling Good Research Practices Task Force. Modeling good research practices. 2012. Available from: http://www.ispor.org/ TaskForces/GRPModelingTf.asp
36. Rituxan [package insert]. South San Francisco, CA: Genentech Inc.; 2011.